Celgene Corp. (CELG)

97.15
0.15 0.15
NASDAQ : Health Technology
Prev Close 97.30
Open 97.38
Day Low/High 97.00 / 97.89
52 Wk Low/High 58.59 / 97.15
Volume 4.52M
Avg Volume 6.79M
Exchange NASDAQ
Shares Outstanding 705.26M
Market Cap 68.06B
EPS 5.70
P/E Ratio 14.73
Div & Yield N.A. (N.A)

My Takeaways and Observations (Afternoon Edition)

"If it is what you say I love it...." - Donald Trump Jr Risk Happens Fast -- and the reverberations of today's disclosures may weigh on the markets for a while as the Administration's initiatives get further lost in the bowels of Washington DC.   Th...

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

My Takeaways and Observations

"I'd unravel every riddle for any individ'le, In trouble or in pain. With the thoughts I'd be thinkin' I could be another Lincoln If I only had a brain." -- "If I Only Had A Brain" (Harold Arlen and E.Y. Harburg), from "The Wizard of Oz" I believe I...

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

The Market Advance Narrows

"For a day where the S&P was essentially flat, there was a lot going on beneath the surface. Just a few days ago, everyone was so excited about the rally, but I pointed out that the cumulative advance/decline line (breadth) had not made a higher hig...

Cramer: This Is No Country for Old Value

Cramer: This Is No Country for Old Value

Down-and-out stocks have become toxic.

Celgene Bucks Biotech Trend

Stocks wrapped up a directionless day of trading near even. Despite the turmoil in D.C., volatility in the market remains remarkably low. Celgene bucked the slightly downward trend in biotech as Leerink Swann reiterated its Buy rating. Oppenheimer d...

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Takeaways and Observations

  Top 10 Reasons the Lambs May Be Sheared ... or Slaughtered.    Stated simply, I see a trend change.   Hello uncertainty and volatility.    My pledge to all of the subs.    No, the tech selloff is not healthy and may not be an opportunity.  And som...

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

Cramer: You Need 2 Monday Morning Game Plans

Cramer: You Need 2 Monday Morning Game Plans

We really want to shake out the weak hands here.

Today's Takeaways and Observations (Afternoon Edition)

"How does it feel, how does it feel? To be without a home Like a complete unknown, like a rolling stone." -- Bob Dylan, Like A Rolling Stone  "The Edifice Complex."   The message of the bond market is clear -- slowing inflation, economic growth and ...

Unsexy Celgene, Toll Brothers Turn Me On

Unsexy Celgene, Toll Brothers Turn Me On

The two aren't among today's hot names, but are solid long-term growth plays.

Cramer: Rally Is Earning Some Trust

Cramer: Rally Is Earning Some Trust

The market rally broadened out nicely today.

Takeaways and Observations

I spent most of the time in my Diary discussing banks. -- and why I am now short the sector and have placed three money centers on my Best Ideas List (short).   And I consistently noted the correlation between yields and banks...and, in turn, a mode...

Charting the Biotechs

Charting the Biotechs

Time to revisit some stocks now that biotech has cooled.

Patience Is a Virtue for Biotech Investing

Patience Is a Virtue for Biotech Investing

Valuations in some large-caps are compelling over the long term.

Takeaways and Observations

"Success breeds complacency. Complacency breeds failure. Only the paranoid survive." - Andy Grove   Perhaps this qualifies as a potential warning from "Uncle" Bob Farrell's ten lessons of investing.   Frankly, I thought dumping Ford's Fields was idi...

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

Takeaways and Observations

"She's a witch of trouble in electric blue, In her own mad mind she's in love with you. With you. Now what you gonna do? Strange brew, kill what's inside of you." -- Cream, Strange Brew     Strange brew!    You have probably forgotten October, 1987....

Added to Allergan on Weakness

Allergan , a day ahead of its earnings release, is down by over $4 on no apparent news, save a rotation out of biotech. (iShares Nasdaq Biotechnology is -3% or -$7 and we see individual equity declines in Celgene , Gilead , Acadia Pharmaceuticals , ...

Earnings: Assessing 3 Biotech Bellwethers

Earnings: Assessing 3 Biotech Bellwethers

How did Celgene, AbbVie and Gilead fare last quarter?

Celgene Has Loads of Potential

Celgene Has Loads of Potential

This stock is poised for more upside.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Early-Morning Earnings Extravaganza

It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...